| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.74▲ | 1.74▲ | 1.72▲ | 1.69▲ | 1.48▲ |
| MA10 | 1.72▲ | 1.72▲ | 1.71▲ | 1.63▲ | 1.36▲ |
| MA20 | 1.71▲ | 1.72▲ | 1.74▲ | 1.43▲ | 1.55▲ |
| MA50 | 1.74▲ | 1.75▲ | 1.72▲ | 1.32▲ | 3.09▼ |
| MA100 | 1.75▲ | 1.66▲ | 1.49▲ | 1.57▲ | 14.29▼ |
| MA200 | 1.73▲ | 1.45▲ | 1.37▲ | 2.64▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.009▲ | 0.007▲ | -0.004▼ | 0.040▲ | 0.286▲ |
| RSI | 58.139▲ | 55.417▲ | 54.372▲ | 64.852▲ | 40.912▼ |
| STOCH | 76.190 | 74.444 | 59.810 | 33.494 | 31.114 |
| WILL %R | 0.000▲ | 0.000▲ | -45.238 | -62.569 | -61.862 |
| CCI | 150.732▲ | 134.277▲ | 85.730 | 52.448 | 108.364▲ |
|
Thursday, November 06, 2025 06:25 AM
Access the “What This Means” segment here CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the ...
|
|
Wednesday, October 29, 2025 07:23 AM
ERNA-101 is based on Ernexa’s technology that engineers induced pluripotent stem cells into induced mesenchymal stem cells (iMSCs), which have a unique ability to migrate toward tumors. The therapy is ...
|
|
Wednesday, October 29, 2025 06:32 AM
THE WOODLANDS, Texas, and CAMBRIDGE, Mass., Oct. 29, 2025 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced it ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 07/11/25 | 1.72 | 1.765 | 1.70 | 1.765 | 61,526 |
| 06/11/25 | 1.73 | 1.78 | 1.64 | 1.69 | 129,000 |
| 05/11/25 | 1.68 | 1.7999 | 1.64 | 1.65 | 152,258 |
| 04/11/25 | 1.61 | 1.89 | 1.61 | 1.68 | 353,285 |
| 03/11/25 | 1.88 | 1.89 | 1.63 | 1.67 | 444,700 |
| 31/10/25 | 1.64 | 1.92 | 1.6201 | 1.88 | 725,268 |
| 30/10/25 | 1.75 | 1.78 | 1.52 | 1.78 | 2,420,600 |
| 29/10/25 | 2.175 | 2.8599 | 1.51 | 1.76 | 211,145,538 |
| 28/10/25 | 1.23 | 1.26 | 1.20 | 1.25 | 11,931 |
| 27/10/25 | 1.22 | 1.23 | 1.19 | 1.19 | 14,100 |
|
|
||||
|
|
||||
|
|